Northamptonshire Healthcare NHS Foundation Trust and Northampton University, Northampton, United Kingdom.
J Clin Psychopharmacol. 2013 Feb;33(1):63-8. doi: 10.1097/JCP.0b013e31827a813b.
Clozapine is superior to other antipsychotic drugs for treatment of refractory schizophrenia. However, its use has been limited by its potentially serious adverse effects. There is little guidance on the management of patients who discontinue clozapine for reasons such as lack of response, intolerance, or noncompliance. The literature was searched for studies on the efficacy of antipsychotics that replaced clozapine in such patients. The search revealed 15 papers, which were evaluated in this article. Olanzapine was the most tested alternative to clozapine with most of the studies reporting positive outcome, especially in patients with less severe illness and those who stop clozapine for reasons other than poor response. Other antipsychotics were not adequately tested in this manner. We concluded that in patients who discontinue clozapine, considering a trial of olanzapine would be worthwhile.
氯氮平在治疗难治性精神分裂症方面优于其他抗精神病药物。然而,由于其潜在的严重不良反应,其应用受到限制。对于因无反应、不耐受或不依从等原因而停用氯氮平的患者,缺乏管理方面的指导。本文对替代此类患者氯氮平的抗精神病药物的疗效进行了研究。该检索发现了 15 篇论文,对其进行了评估。奥氮平是替代氯氮平的研究最多的药物,大多数研究报告了积极的结果,尤其是在病情较轻的患者和因无反应以外的原因而停用氯氮平的患者中。其他抗精神病药物未以这种方式进行充分的测试。我们的结论是,对于停用氯氮平的患者,考虑试用奥氮平可能是值得的。